Alimera Sciences (ALIM) Reports U.K. NICE Deems ILUVIEN Not Cost Effective as DME Treatment
Go back to Alimera Sciences (ALIM) Reports U.K. NICE Deems ILUVIEN Not Cost Effective as DME Treatment| ALIMERA SCIENCES (NASDAQ: ALIM) | Delayed: 5.54 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.54 | 52 Week High | $5.15 | |||
| Open | $5.54 | 52 Week Low | $1.02 | |||
| Day High | $5.54 | P/E | N/A | |||
| Day Low | $5.54 | EPS | $-1.16 | |||
| Volume | 5,700 | |||||
